Cutaneous melanoma is a common cancer and cases have steadily increased since the mid 70s.For some patients,early diagnosis and surgical removal of melanomas is lifesaving,while other patients typically turn to molecu...Cutaneous melanoma is a common cancer and cases have steadily increased since the mid 70s.For some patients,early diagnosis and surgical removal of melanomas is lifesaving,while other patients typically turn to molecular targeted therapies and immunotherapies as treatment options.Easy sampling of melanomas allows the scientific community to identify the most prevalent mutations that initiate melanoma such as the BRAF,NRAS,and TERT genes,some of which can be therapeutically targeted.Though initially effective,many tumors acquire resistance to the targeted therapies demonstrating the need to investigate compensatory pathways.Immunotherapies represent an alternative to molecular targeted therapies.However,inter-tumoral immune cell populations dictate initial therapeutic response and even tumors that responded to treatment develop resistance in the long term.As the protocol for combination therapies develop,so will our scientific understanding of the many pathways at play in the progression of melanoma.The future direction of the field may be to find a molecule that connects all of the pathways.Meanwhile,noncoding RNAs have been shown to play important roles in melanoma development and progression.Studying noncoding RNAs may help us to understand how resistance e both primary and acquired e develops;ultimately allow us to harness the true potential of current therapies.This review will cover the basic structure of the skin,the mutations and pathways responsible for transforming melanocytes into melanomas,the process by which melanomas metastasize,targeted therapeutics,and the potential that noncoding RNAs have as a prognostic and treatment tool.展开更多
SATB2(special AT-rich sequence-binding protein 2)is a member of the special AT-rich binding protein family.As a transcription regulator,SATB2 mainly integrates higher-order chromatin organization.SATB2 expression appe...SATB2(special AT-rich sequence-binding protein 2)is a member of the special AT-rich binding protein family.As a transcription regulator,SATB2 mainly integrates higher-order chromatin organization.SATB2 expression appears to be tissue-and stage-specific,and is governed by several cellular signaling molecules and mediators.Expressed in branchial arches and osteoblast-lineage cells,SATB2 plays a significant role in craniofacial pattern and skeleton development.In addition to regulating osteogenic differentiation,SATB2 also displays versatile functions in neural development and cancer progression.As an osteoinductive factor,SATB2 holds great promise in improving bone regeneration toward bone defect repair.In this review,we have summarized our current understanding of the physiological and pathological functions of SATB2 in craniofacial and skeleton development,neurogenesis,tumorigenesis and regenerative medicine.展开更多
基金The reported work was supported in part by research grant from the National Institutes of Health(CA226303 to TCH,and DE030480 to RRR)WW was supported by the Medical Scientist Training Program of the National Institutes of Health(T32 GM007281)+2 种基金This project was also supported in part by The University of Chicago Cancer Center Support Grant(P30CA014599)the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1 TR000430TCH was also supported by the Mabel Green Myers Research Endowment Fund and The University of Chicago Orthopaedics Alumni Fund.
文摘Cutaneous melanoma is a common cancer and cases have steadily increased since the mid 70s.For some patients,early diagnosis and surgical removal of melanomas is lifesaving,while other patients typically turn to molecular targeted therapies and immunotherapies as treatment options.Easy sampling of melanomas allows the scientific community to identify the most prevalent mutations that initiate melanoma such as the BRAF,NRAS,and TERT genes,some of which can be therapeutically targeted.Though initially effective,many tumors acquire resistance to the targeted therapies demonstrating the need to investigate compensatory pathways.Immunotherapies represent an alternative to molecular targeted therapies.However,inter-tumoral immune cell populations dictate initial therapeutic response and even tumors that responded to treatment develop resistance in the long term.As the protocol for combination therapies develop,so will our scientific understanding of the many pathways at play in the progression of melanoma.The future direction of the field may be to find a molecule that connects all of the pathways.Meanwhile,noncoding RNAs have been shown to play important roles in melanoma development and progression.Studying noncoding RNAs may help us to understand how resistance e both primary and acquired e develops;ultimately allow us to harness the true potential of current therapies.This review will cover the basic structure of the skin,the mutations and pathways responsible for transforming melanocytes into melanomas,the process by which melanomas metastasize,targeted therapeutics,and the potential that noncoding RNAs have as a prognostic and treatment tool.
基金This reported work was supported in part by research grants from the National Natural Science Foundation of China(No.#81870758 to HZ)Chongqing Research Program of Basic Research and Frontier Technology(No.#cstc2017jcyjAX0020 to HZ).
文摘SATB2(special AT-rich sequence-binding protein 2)is a member of the special AT-rich binding protein family.As a transcription regulator,SATB2 mainly integrates higher-order chromatin organization.SATB2 expression appears to be tissue-and stage-specific,and is governed by several cellular signaling molecules and mediators.Expressed in branchial arches and osteoblast-lineage cells,SATB2 plays a significant role in craniofacial pattern and skeleton development.In addition to regulating osteogenic differentiation,SATB2 also displays versatile functions in neural development and cancer progression.As an osteoinductive factor,SATB2 holds great promise in improving bone regeneration toward bone defect repair.In this review,we have summarized our current understanding of the physiological and pathological functions of SATB2 in craniofacial and skeleton development,neurogenesis,tumorigenesis and regenerative medicine.
